Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Galena Biopharma Inc    

 SummaryNewsCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2017 -
EBIT 2017 -20,7 M
Net income 2017 -19,6 M
Debt 2017 -
Yield 2017 -
Sales 2018 -
EBIT 2018 -51,8 M
Net income 2018 -53,8 M
Debt 2018 -
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales2017 0
Capi. / Sales2018 0
Capitalization 21,8 M
More Financials
Company
Galena Biopharma, Inc. is a biopharmaceutical company committed to the development and commercialization of hematology and oncology therapeutics that address unmet medical needs.It focuses on identifying and advancing therapeutic opportunities to improve cancer care from direct treatment of the... 
Sector
Pharmaceuticals
Calendar
08/15Earnings Release
More about the company
Latest news on GALENA BIOPHARMA INC
07/12 Galena Biopharma Provides Corporate Update
07/11 GALENA BIOPHARMA, INC. (NASDAQ : GALE) Files An 8-K Entry into a Material Defini..
07/11 GALENA BIOPHARMA, INC. : Entry into a Material Definitive Agreement, Financial S..
07/06 GALENA BIOPHARMA, INC. (NASDAQ : GALE) Files An 8-K Submission of Matters to a V..
07/06 GALENA BIOPHARMA, INC. : Submission of Matters to a Vote of Security Holders (fo..
06/12 GALENA BIOPHARMA, INC. : Submission of Matters to a Vote of Security Holders (fo..
06/06 GALENA BIOPHARMA, INC. : Termination of a Material Definitive Agreement (form 8-..
05/11 GALENA BIOPHARMA : reports 1Q loss
05/10 GALENA BIOPHARMA : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION A..
05/10 GALENA BIOPHARMA, INC. (NASDAQ : GALE) Files An 8-K Results of Operations and Fi..
More news
Sector news : Pharmaceuticals - NEC
07/21 FTSE, sheltered from euro strength, has best week since May
07/21DJGLAXOSMITHKLINE : FDA Approves Injectable Form Of Glaxo's Benlysta
07/21 GlaxoSmithKline's new CEO prepares to trim drug pipeline
07/21 AstraZeneca CEO reassures staff, aims to be at September cancer meet
07/20 Abbott profit forecast gets a lift from St. Jude integration
More sector news : Pharmaceuticals - NEC
Latest Tweets
07/12Galena Biopharma Provides Corporate Update  
07/12BRIEF-Galena Biopharma updates on exploring strategic options  
07/01Galena Biopharma $GALE Earning Somewhat Critical Press Coverage, Accern Repor.. 
06/28Somewhat Favorable News Coverage Very Likely to Impact Galena Biopharma $GALE.. 
06/21Galena Biopharma $GALE Receiving Somewhat Favorable News Coverage, Report Fin.. 
More tweets
Qtime:13
News from SeekingAlpha
2016 Galena Biopharma's (GALE) CEO Mark Schwartz on Q3 2016 Results - Earnings Cal..
2016 Galena Biopharma beats by $0.02
2016 Notable earnings after Wednesday?s close
2016 RXI PHARMACEUTICALS : Moving On Promising Scar Treatment
2016 Best And Worst Performing Stocks Of 2016
Technical analysis trends GALENA BIOPHARMA INC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
 
Mean consensus HOLD
Number of Analysts 3
Average target price -
Spread / Average Target -100%
EPS Revisions
Managers
NameTitle
Stephen F. Ghiglieri CEO, CFO & Principal Accounting Officer
Sanford J. Hillsberg Chairman
Bijan Nejadnik Chief Medical Officer & Executive Vice President
Stephen S. Galliker Independent Director
Rudolph Nisi Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
GALENA BIOPHARMA INC22
JOHNSON & JOHNSON17.45%364 503
ROCHE HOLDING LTD.4.90%221 492
NOVARTIS8.37%220 936
PFIZER3.08%199 378
MERCK AND COMPANY6.39%171 303